Steady-State Pharmacokinetics of a New Antipsychotic Agent Perospirone and Its Active Metabolite, and Its Relationship with Prolactin Response
Authors:
- Norio Yasui-FurukoriNYNorio Yasui-Furukori
- Hanako FurukoriHFHanako Furukori
- Taku NakagamiTNTaku Nakagami
- Manabu SaitoMSManabu Saito
- Yoshimasa InoueYIYoshimasa Inoue
- Sunao KanekoSKSunao Kaneko
- Tomonori TateishiTTTomonori Tateishi
- 1 August 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 26 (4) , 361-365
Abstract
The authors investigated steady-state pharmacokinetics of perospirone and its active metabolite hydroxyperospirone (ID-15036) and its prolactin response in 10 schizophrenic patients receiving 16 mg twice daily. Plasma concentrations of perospirone, hydroxyperospirone, and prolactin were monitored just before and up to 12 hours after the dosing. Thereafter, the dose was decreased to 8 mg twice daily in 8 patients, and drug concentrations were determined. The geometric means of peak concentration (Css max), time to C ss max(tmax), area under the plasma concentration-time curve from 0 to 12 hours [AUC (0–12)], and elimination half-life at steady state were 8.8 ng/mL, 0.8 hours, 22.0 ng·h/mL, and 1.9 hours, respectively, for perospirone, and those of Css max, tmax, and AUC (0–12) for hydroxyperospirone were 29.4 ng/mL, 1.1 hours, and 133.7 ng·h/mL, respectively. There were no differences in dose-normalized Css max or AUC (0–12) perospirone and hydroxyperospirone between 16 mg/day and 32 mg/day of perospirone. Changes in prolactin concentration from 1 to 2 hours after the dosing were parallel with drug concentrations, and almost normal ranges of prolactin concentration were observed before the morning dose despite steady state. The current study indicated that perospirone is rapidly absorbed and rapidly eliminated, which influences the prolactin response. The active metabolite hydroxyperospirone may play an important role in the antipsychotic effect because the plasma concentration of this metabolite is higher than that of the parent compound.Keywords
This publication has 13 references indexed in Scilit:
- Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatographyJournal of Chromatography B, 2003
- In vitro metabolism of perospirone in rat, monkey and human liver microsomesEuropean Journal of Drug Metabolism and Pharmacokinetics, 2003
- Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to ClozapineAmerican Journal of Psychiatry, 2001
- PerospironeCNS Drugs, 2001
- Single Oral Dose Kinetics of Zotepine and Its Relationship to Prolactin Response and Side EffectsTherapeutic Drug Monitoring, 1998
- In Vitro Receptor Binding and In Vivo Receptor Occupancy in Rat and Guinea Pig Brain: Risperidone Compared with Antipsychotics Hitherto UsedThe Japanese Journal of Pharmacology, 1995
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Binding Profile of SM-9018, a Novel Antipsychotic CandidateThe Japanese Journal of Pharmacology, 1990
- Pharmacokinetics of HaloperidolClinical Pharmacokinetics, 1989
- Pharmacokinetics of chlorpromazine after single and chronic dosageClinical Pharmacology & Therapeutics, 1977